Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Inc (NQ: VCYT ) 23.57 +0.54 (+2.34%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Veracyte Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules November 29, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 November 22, 2023 From Veracyte, Inc. Via Business Wire Are You A Trader Or Investor: Biotech Momentum Is Picking Up November 20, 2023 ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. Via Talk Markets Topics ETFs Veracyte: Q3 Earnings Insights November 07, 2023 Via Benzinga The Latest Analyst Ratings for Veracyte October 20, 2023 Via Benzinga Veracyte Announces Third Quarter 2023 Financial Results November 07, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally November 07, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the Stephens Annual Investment Conference November 02, 2023 From Veracyte, Inc. Via Business Wire Earnings Scheduled For November 7, 2023 November 07, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. Via Benzinga Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development October 27, 2023 From Veracyte, Inc. Via Business Wire 7 Undervalued Stocks That Analysts Love Right Now October 26, 2023 With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal. Via InvestorPlace Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 October 17, 2023 From Veracyte, Inc. Via Business Wire New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease October 12, 2023 From Veracyte, Inc. Via Business Wire Veracyte Stock Is Volatile After-Hours - Here's Why October 04, 2023 Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier... Via Benzinga New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier October 04, 2023 From Veracyte, Inc. Via Business Wire New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer September 28, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 September 28, 2023 From Veracyte, Inc. Via Business Wire Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer September 27, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting September 21, 2023 From Veracyte, Inc. Via Business Wire Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests September 07, 2023 From Veracyte, Inc. Via Business Wire Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies September 06, 2023 From Veracyte, Inc. Via Business Wire Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? September 02, 2023 The genetic test maker is rapidly increasing test volumes. Via The Motley Fool Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference August 29, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer August 22, 2023 From Veracyte, Inc. Via Business Wire Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego August 15, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Second Quarter 2023 Financial Results August 08, 2023 From Veracyte, Inc. Via Business Wire Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment August 01, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023 July 19, 2023 From Veracyte, Inc. Via Business Wire Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom July 08, 2023 AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider. Via InvestorPlace New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer June 20, 2023 From Veracyte, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.